Feedback / Questions
efdamrofusp alfa (IBI302) - Innovent Biologics
https://www.prnewswire.com/news-releases/innovent-announces-primary-endpoint-met-in-the-second-phase-2-clinical-trial-of-ibi302-anti-vegfcomplement-in-treating-neovascular-age-related-macular-degeneration-namd-302091578.html
Mar 18, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next